

Epidermal Expression of the Translation Inhibitor Programmed Cell Death 4 Suppresses Tumorigenesis

Aaron P. Jansen, Corinne E. Camalier, and Nancy H. Colburn

Gene Regulation Section, Laboratory of Cancer Prevention, Center for Cancer Research, National Cancer Institute, Frederick, Maryland

Abstract

Programmed cell death 4 (Pcdcd4) is a novel repressor of *in vitro* transformation. Pcdcd4 directly inhibits the helicase activity of eukaryotic translation initiation factor 4A, a component of the translation initiation complex. To ascertain whether Pcdcd4 suppresses tumor development *in vivo*, we have generated transgenic mice that overexpress Pcdcd4 in the epidermis (K14-Pcdcd4). K14-regulated Pcdcd4 expression caused a neonatal short-hair phenotype due to early catagen entry compared with matched wild-type siblings. In response to the 7,12-dimethylbenz(a)anthracene (DMBA)/12-*O*-tetradecanoylphorbol-13-acetate (TPA) mouse skin carcinogenesis protocol, K14-Pcdcd4 mice showed significant reductions in papilloma formation, carcinoma incidence, and papilloma-to-carcinoma conversion frequency compared with wild-type mice. The translational efficiency of an mRNA engineered to form a structured 5' untranslated region (UTR) was attenuated in primary keratinocytes when Pcdcd4 was overexpressed. Pcdcd4 inhibited by 46% TPA-induced activator protein-1 (AP-1)-dependent transcription, an event required for tumorigenesis. CDK4 and ornithine decarboxylase (ODC) are candidates for Pcdcd4-regulated translation as their mRNAs contain 5' structured UTRs. In K14-Pcdcd4 primary keratinocytes expressing activated Ha-Ras to mimic DMBA-initiated epidermis, ODC and CDK4 protein levels were decreased by 40% and 46%, respectively. Expression of a protein encoded by 5' unstructured mRNA showed no change. These results extend to an *in vivo* model the observations that Pcdcd4 inhibits both translation initiation and AP-1 activation while decreasing benign tumor development and malignant progression. The K14-Pcdcd4 mice seem to validate translation initiation as a novel target for cancer prevention. (Cancer Res 2005; 65(14): 6034-41)

Introduction

Eukaryotic cells regulate gene expression at multiple levels, among them transcription, splicing, stability, and translation of mRNA. Whereas transcriptional dysregulation is a well-studied contributor to cancer pathogenesis, increasing evidence implicates altered translational regulation as well (1, 2). Translation initiation is the predominant rate-limiting step for most mRNAs during protein synthesis. Expression of a translation initiation factor, eukaryotic translation initiation factor 4E (eIF4E), malignantly transforms rodent fibroblasts via downstream activation of Ras and acts directly as an oncogene in mice (3–5). Exposure to skin tumor

promoters, such as 12-*O*-tetradecanoylphorbol-13-acetate (TPA), enhances the formation of the translation initiation complex (6). Several tumors and tumor cell lines show elevated levels of components of the translation initiation complex, including eIF4A (7, 8), eIF4E (9), and eIF4G (10). Translation-dependent transcription has been suggested as a possible immediate early outcome of combined oncogenic assault by Akt and Ras. Coexpression of Akt with Ras produces increased recruitment of specific transcripts to the ribosome and consequently enhanced translation rate before induction of gene transcription (11). Therefore, inhibitory regulation of translation initiation factors may prevent or inhibit cancer induction.

Several eukaryotic translation initiation factors, including the eIF4F complex, participate in the translation initiation process. eIF4F is a multiple-subunit complex comprised of the scaffold protein eIF4G, the cap-binding protein eIF4E, and the RNA helicase enzyme eIF4A. eIF4E recruits capped mRNA to the initiation complex, completing the formation of eIF4F and facilitating the unwinding of structured mRNA by eIF4A, thus making possible ribosome binding. Current evidence suggests that the cap-binding activity of eIF4E is a limiting factor in recruitment of mRNA to the ribosome. However, efficient translation requires the unwinding of the mRNA secondary structure by the ATP-dependent helicase activity of eIF4A (12). Whether eIF4A may also be rate-limiting for translation of specific transcripts is currently unknown.

A novel eIF4A binding partner, programmed cell death 4 (Pcdcd4), has been identified. Pcdcd4 binds to and inhibits the helicase activity of eIF4A, subsequently inhibiting cap-dependent translation (13). Pcdcd4 also binds eIF4G independently of its interaction with eIF4A although the consequence of Pcdcd4 binding to eIF4G is not well understood. Pcdcd4 seems to be the first example of a protein in mammalian cells that inhibits translation through attenuation of eIF4A activity. Pcdcd4 is a novel inhibitor of transformation in cell culture models (14–16). *Pcdcd4* was initially cloned from differential display analysis of JB6 transformation response variants derived from mouse epidermal cells (14). The JB6 model includes variants that are sensitive (P+) or insensitive (P-) to cellular transformation by tumor promoters (17, 18). *Pcdcd4* is highly expressed in transformation-resistant (P-) JB6 cells and functions to inhibit transformation in the JB6 model (14–16).

Pcdcd4 inhibits tumor promoter-induced transformation, at least in part, by inhibiting transactivation of the activator protein-1 (AP-1) transcription factor (15). AP-1-dependent transcription is required for transformation as expression of dominant-negative AP-1 is sufficient to inhibit tumor promotion/progression in the JB6 cell model, in a human keratinocyte progression series, and in a transgenic mouse line expressing an inhibitor of AP-1 (19–21). The inhibition of the AP-1 transactivation by Pcdcd4 seems to be by an upstream indirect mechanism (15). Synthesis of AP-1 proteins is not inhibited by Pcdcd4 (16). In addition, Jun/Fos

Requests for reprints: Aaron P. Jansen, National Cancer Institute-Frederick, Building 567, Room 187, Frederick, MD 21702. Phone: 301-846-6850; Fax: 301-846-6907; E-mail: ajansen@ncifcrf.gov.

©2005 American Association for Cancer Research.

protein concentration is not limiting as ectopic expression of individual AP-1 proteins fails to relieve inhibition of AP-1–dependent transcription by Pdc4 (15). eIF4A and AP-1 seem to be linked via Pdc4. A Pdc4 mutant that is inactivated for binding to eIF4A is inactivated not only for inhibiting translation, but also for inhibiting AP-1 transactivation (13).

Pdc4 is a novel candidate for cancer prevention yet to be assessed *in vivo* in animal models. The mouse skin two-stage carcinogenesis model has been productive in defining the irreversible genetic events of initiation and progression and the required threshold signaling events of tumor promotion during neoplastic development (22–26). To investigate whether overexpression of Pdc4 may prevent or inhibit tumorigenesis *in vivo*, we generated a transgenic mouse model in which expression of Pdc4 was directed to the epidermis by the human keratin 14 promoter. Pdc4 expression inhibited translation of a luciferase transcript containing a structured 5′ untranslated region (UTR) and inhibited tumor promoter–induced AP-1 activity *in vivo*. Moreover, Pdc4 expression provided resistance to tumor promotion and tumor progression in response to a multistage carcinogenesis regimen. These results support the hypothesis that Pdc4 is an inhibitor of multistage carcinogenesis and suggest that targeting translation initiation may be a promising approach to cancer prevention.

Materials and Methods

Materials. TPA was purchased from Alexis Biochemical (San Diego, CA). 7,12-Dimethylbenz(*a*)anthracene (DMBA), anti-FLAG antibody, and _{met}FLAG cDNA sequence were purchased from Sigma-Aldrich (St. Louis, MO). Peptide purified anti-Pdc4 antibody was described previously (27). Anti-CDK4 and anti-ornithine decarboxylase (ODC) antibodies were purchased from Santa Cruz Biotechnologies (Santa Cruz, CA). Anti-eIF4A antibody was a generous gift from Bill Merrick (Case Western Reserve University, Cleveland, OH).

Generation and identification of K14-Pdc4 transgenic mice. Murine _{met}FLAG-Pdc4 cDNA was inserted into the hK14-hGH vector. DNA sequence for murine *pdc4* was identical to previously published sequence (accession no. NM 011050). The hK14-hGH vector was characterized previously (28). The 6.5 kb K14-_{met}FLAG-Pdc4 expression cassette was removed from the vector by digestion with *Kpn*I and *Hind*III, purified, and microinjected into the pronuclei of fertilized FVB/N mouse oocytes. Eight founders were positive for the transgene determined by Southern analysis of *Bam*HI-digested tail DNA. Subsequent identifications of transgenic mice were determined by PCR utilizing human specific K14 promoter based primers previously described (21). Mice were maintained in accordance with NIH guidelines.

Histology and immunohistochemistry. For the histology done to examine the hair cycle, animals were sacrificed at postnatal days 9, 12, 16, and 19. The dorsal skin was excised from approximately identical regions among the mice and fixed overnight in 10% buffered formalin, transferred to 70% ethanol, paraffin-embedded, and H&E stained. Age- and sex-match littermates were grouped, and the hair status was determined by morphologic examination.

For immunohistochemistry to show Pdc4 expression, tissues were fixed in 4% paraformaldehyde (24 hours) and embedded in paraffin. Four-micrometer sections were cut for H&E staining or immunostaining. Deparaffinized slides were hydrated, trypsinized, blocked for endogenous peroxidase activity, preincubated with goat serum, incubated with anti-Pdc4 antibody (1:200), and visualized with Rabbit IgG Vectastain ABC kit and DAB Peroxidase Substrate kit (Vector Laboratories, Burlingame, CA).

TPA-induced epithelial proliferation was measured by topically treating the dorsal skin with 5 nmol TPA or solvent control (acetone). Twenty-two hours after TPA treatment, mice were given by i.p. injection with 5-bromodeoxyuridine (BrdUrd) at 250 mg/kg body weight in 100 μ L PBS and

sacrificed 2 hours postinjection. Dorsal skin from approximately the same area on each mouse was fixed for 20 hours in 10% neutral buffered formalin, transferred to 70% ethanol, and processed immediately. BrdUrd incorporation was detected by immunohistochemical staining of paraffin-embedded sections. The percentage of positive staining was determined by observing 1,000 interfollicular basal keratinocytes for each mouse skin. Each treatment was done in three mice. To determine the percentage of apoptotic cells, the same skin sections were analyzed for positive staining by terminal deoxynucleotidyl transferase (TdT)–mediated nick-end nucleotide labeling (TUNEL).

Isolation of primary keratinocytes. Primary keratinocytes were harvested from 2- to 4-day-old postnatal pups as described previously (29).

Western blot analysis. Mice were euthanized and the shaved; the dorsal skin was removed. Epidermis was separated from the dermis by scraping or papillomas were ground in liquid nitrogen. Both types of samples were homogenized with 5 volumes of Tris/SDS extraction buffer [10 mmol/L Tris-HCl (pH 7.4), 0.1% SDS plus protease inhibitors]. The homogenate was centrifuged at 14,000 $\times g$ for 30 minutes at 4°C, and the supernatant was fractionated on 10% SDS-PAGE. The proteins were transferred to nitrocellulose membrane and incubated with specific antibodies, detected using the appropriate secondary antibodies and visualized with ECL (Amersham Bioscience, Piscataway, NJ).

Virus production and candidate Pdc4 target analysis. To investigate candidate Pdc4 target proteins encoded by 5′ structured mRNAs, primary keratinocytes from either Pdc4 transgenic or wild-type mice were infected with a replication-defective retrovirus containing the activated *ras^{Ha}* gene, called pBabepuroRasV12 or control pBabepuro (30). High-titer retroviral supernatants were obtained through transient transfection of retroviral plasmid DNA into the Ecopak packaging cell line (BD Biosciences, Franklin Lakes, NJ). After retroviral infection at a multiplicity of infection of 0.5 to 1, cells underwent puromycin selection. Cells were grown in puromycin-free media for 48 hours before harvest. The extracts were analyzed for steady-state protein levels of candidates for Pdc4-specific attenuation via Western blot analysis.

Two-stage chemical carcinogenesis. Seven- to eight-week-old mice were initiated with a single topical application of DMBA (100 nmol/0.2 mL acetone) to the shaved backs. Two weeks later, TPA (5 nmol/0.2 mL acetone) or acetone alone was applied twice weekly to the initiated skin for 26 weeks (K14-Pdc4-C1, *n* = 16; K14-Pdc4-G6, *n* = 14; wild-type FVB/N, *n* = 37). Carcinomas were recorded grossly as downward-invading lesions, and malignancy was confirmed histologically as invading the panniculus carnosus.

Activator protein-1 luciferase activity. AP-1 luciferase activity was measured in primary keratinocytes derived from a cross between AP-1–Luciferase (AP-1–Luc) reporter mice (31) and K14-Pdc4 mice, which produced AP-1–Luc/K14-Pdc4 bitransgenic pups and AP-1–Luc transgenic siblings. Primary keratinocytes were plated overnight and treated for 13 hours with the indicated dose of TPA dissolved in DMSO or DMSO alone (0.1% final DMSO concentration). Cellular extracts were collected after lysis with Passive Lysis Buffer (Promega, Madison, WI). Luciferase activity was determined from lysates (25 μ L) in a MLX Luminometer (Dynex Technologies, Chantilly, VA) and normalized to total DNA content.

Translational activity. A translation assay of the luciferase and structured luciferase reporter system was described previously (13). Primary keratinocyte cells from K14-Pdc4-G6 and wild-type siblings were seeded in a 24-well plate and were transfected with 80 ng of pcDNA-LUC (luciferase) or pcDNA-SL-LUC (structured luciferase) and 20 ng RL-TK using Fugene6 (Roche Diagnostics, Indianapolis, IN). Cells were serum starved for 24 hours and incubated with medium + 10% chelexed fetal bovine serum for 20 hours. Cells were lysed in 1 \times passive lysis buffer. Luciferase activity was measured and normalized to renilla luciferase activity using the Dual-Luciferase Reporter Assay System (Promega) and an MLX luminometer.

Statistical analysis. Two-sided *P* values were calculated for papilloma multiplicity by Wilcoxon rank sum test, for tumor incidence and progression frequency by Fisher's exact test, and for AP-1 luciferase and stem-loop luciferase activity by Student's *t* test.

Results

Transgenic gain of Pcdcd4 expression in epidermis is cytoplasmic and causes transient short-hair phenotype. *In vitro* models suggest that Pcdcd4 may negatively regulate cellular transformation. To determine whether overexpression of the Pcdcd4 conferred resistance to multistage carcinogenesis, we generated transgenic mice expressing FLAG epitope-tagged Pcdcd4 in the epidermis directed by the human keratin 14 promoter (hK14-hGH, called K14; refs. 21, 28).

All founders were bred to wild-type FVB/N mice to produce F₁ offspring in which the characterization of each line was done. Relative transgenic expression levels were determined by Western blot analysis of epidermal protein extracts with anti-Pcdcd4 antibody. Two lines, hK14-FLAG-Pcdcd4-G6 (Pcdcd4-G6) and hK14-FLAG-Pcdcd4-C1 (Pcdcd4-C1), showed the highest levels of transgenic and total Pcdcd4 expression. Of note, both lines independently displayed short-hair phenotype, which was evident during the first hair cycle up until 7 weeks of age (Fig. 1B).

Wild-type and transgenic primary keratinocytes were cultured and protein extracts were collected for the purpose of determining relative Pcdcd4 protein levels in basal keratinocytes. Overall Pcdcd4 protein levels in Pcdcd4-C1 and Pcdcd4-G6 primary keratinocytes were increased 4-fold and 10-fold, respectively, as determined after Western blot analysis with anti-Pcdcd4 antibody followed by densitometric analysis of Pcdcd4-specific bands (Fig. 1A, middle). Both Pcdcd4-C1 and Pcdcd4-G6 keratinocytes displayed an increase in exogenous protein level determined after Western blot analysis with anti-FLAG antibody (Fig. 1A, top). Note that a low-expressing FLAG cross-reactive protein migrated as a doublet at approximately the same location as Pcdcd4 (54 kDa). Although Pcdcd4 binds to eIF4A and inhibits its activity, no compensatory elevation in eIF4A protein was detected in either Pcdcd4-C1 or Pcdcd4-G6 transgenic mice compared with wild-type. Thus, eIF4A served as a suitable loading control (Fig. 1A, bottom).

To determine the pattern of expression of Pcdcd4 in the transgenic mouse skin, we did immunohistochemical staining using the anti-Pcdcd4 antibody on sections of mouse skin. Pcdcd4 was expressed in the outer root sheath of the hair follicle and interfollicular epidermis. Pcdcd4 displayed diffuse cytoplasmic staining and an apparent lack of nuclear staining in wild-type mice, as indicated by the lack of Pcdcd4 staining in hematoxylin-positive nuclei (Fig. 1C). Pcdcd4 staining of transgenic Pcdcd4-G6 skin showed localization similar to wild-type siblings but seemed markedly increased (Fig. 1D).

To further characterize the neonatal short-hair phenotype of Pcdcd4-G6 and Pcdcd4-C1 mice, skin of age- and sex-matched pups was harvested from the mid-dorsal region beginning at postnatal day 9 and continuing on days 12, 16, and 19. At day 16 postpartum during the primary hair cycle, the wild-type hair follicles remained in anagen with hair follicles embedded in the subcutis (Fig. 1E). However, Pcdcd4 transgenic mice exhibited premature termination of anagen as determined by the complete regression of the hair follicles into the upper dermis (Fig. 1F). The temporal reduction in the primary hair cycle of Pcdcd4 transgenic animals was consistent with presentation of the neonatal short-hair phenotype.

Pcdcd4 inhibits helicase-dependent translation. Pcdcd4 directly binds to and inhibits the helicase activity of eIF4A (13). The translational requirement for eIF4A is directly proportional to the degree of mRNA 5' secondary structure (32). In JB6 cells, Pcdcd4 reduces the translation efficiency of a luciferase reporter




Figure 1. Transgenic expression of Pcdcd4 decreases length of hair through the first hair cycle. *A*, Western blot of protein extract from primary keratinocyte cultured lines (wild type, Pcdcd4-C1, and Pcdcd4-G6), displaying endogenous Pcdcd4 and exogenous FLAG epitope-tagged Pcdcd4 expression by immunoblotting with anti-FLAG, anti-Pcdcd4, or anti-eIF4A antibodies. Note the lack of change in eIF4A protein levels. *B*, photograph of wild-type and Pcdcd4-G6 siblings (28 days old) revealing a shorter hair phenotype due to Pcdcd4 overexpression. *C* and *D*, immunohistochemical staining of Pcdcd4 in wild-type (*C*) and Pcdcd4-G6 (*D*) mouse skin. Note the increase of brown staining within the epidermis and hair follicle in Pcdcd4-G6 skin compared with wild-type skin. *E* and *F*, skin sections were made at 16 days postpartum. The follicles pictured are from similar mid-dorsal regions on both wild-type (*E*) and Pcdcd4-G6 (*F*) mice. Pcdcd4-G6 mice have almost completed catagen and follicles have regressed into the upper dermis. In contrast, the wild-type follicles remain in anagen.

transcript engineered with a 24 bp stem loop ($\Delta G = -44.8$ kcal/mol), inserted 97 nucleotides downstream of the cap of the mRNA (33). The free energy of the 24 bp stem loop seems to be physiologically relevant due to its similarity to the TAR (+111) mRNA of HIV ($\Delta G = -49.9$ kcal/mol; ref. 32). To determine whether the transgenic increase in Pcdcd4 expression altered the *in vivo* translation efficiency of the stem-loop luciferase reporter transcript, wild-type and Pcdcd4-G6 primary keratinocytes were cultured and transfected with plasmids carrying either stem-loop or non-stem-loop luciferase transcripts under the regulation of the CMV promoter. Elevated transgenic Pcdcd4 expression inhibited translation of the stem-loop transcript by 43%, whereas translation of the unstructured mRNA was essentially unaffected.

(Compare Pdc4-G6 and wild-type primary keratinocytes; Fig. 2A.). The translation of the stem-loop luciferase was 2% as efficient as the translation of the non-stem-loop luciferase transcript in wild-type mouse keratinocytes. The Pdc4-specific inhibition of translation of the stem-loop reporter suggests that translation of mRNA transcripts with structured 5' UTRs may be particularly sensitive to Pdc4 expression in transgenic mice.

Both CDK4 and ODC have been reported to be controlled partially at the level of translation due to 5' structured UTRs (34). Comparing K14-Pdc4 and wild-type primary keratinocytes subsequently infected with a retroviral construct expressing activated Ha-Ras to mimic DMBA-initiated epidermis, the immunoreactive protein of candidate genes *ODC* and *CDK4* was decreased by 40% and 46%, respectively (Fig. 2B). There was no difference in 5' unstructured mRNA-encoded eIF4A protein (Fig. 2B) or actin (data not shown) protein levels in transgenic and wild-type primary cultures, suggesting specificity toward mRNA with greater secondary structure. In contrast to protein levels, candidate gene mRNA levels remained equal as determined

by gene array analyses.¹ Thus, translation of both structured luciferase and structured endogenous mRNAs, but not of unstructured mRNAs, is inhibited by Pdc4 expression.

Pdc4 inhibits both basal and tumor promoter-induced transactivation of activator protein-1-dependent transcription. AP-1-dependent transcription is required for tumor promotion in the mouse skin (21). Pdc4 has been shown to inhibit TPA-induced AP-1 transactivation in tissue culture models in a manner dependent on Pdc4 interaction with eIF4A (13, 15). To address whether Pdc4 inhibition of AP-1 transactivation extends to an *in vivo* model, the K14-Pdc4 transgenic mice were bred to AP-1-Luc reporter transgenic mice, which ubiquitously express a luciferase transcript under the regulation of an AP-1-dependent promoter (31). Primary keratinocytes were harvested from pups and pooled according to genotype. AP-1-Luc/Pdc4 bitransgenic cultures were compared with those from AP-1-Luc transgenic siblings negative for Pdc4 transgenic expression. Both basal and TPA-induced AP-1 activity were attenuated in Pdc4-C1/AP-1-Luc and Pdc4-G6/AP-1-Luc bitransgenic keratinocytes (Fig. 3). The inhibition of luciferase activity in transgenic keratinocytes is unlikely to arise from nonspecific inhibition of luciferase mRNA translation, as Pdc4 does not alter translation of the luciferase transcript in JB6 RT101 cells transfected with pCMV-luciferase (33). To determine the specificity of the inhibition of AP-1, the K14-Pdc4 transgenic mice were crossed to nuclear factor- κ B (NF- κ B)-luciferase promoter transgenic mice (35). Keratinocytes were harvested and the relative level of NF- κ B-dependent activity was measured. Although this model could not be analyzed for tumor promoter-induced NF- κ B (as none occurs), analysis of the high basal levels of NF- κ B revealed no inhibition by Pdc4 (data not shown). Thus, as seen in cell culture (15), Pdc4 specifically inhibits AP-1-dependent transcription *in vivo*.

Expression of Pdc4 attenuates both tumor development and tumor progression. Because Pdc4 inhibits transformation and maintenance of tumor phenotype in the JB6 cell culture model, Pdc4 might be expected to provide genetic resistance to multistage carcinogenesis in an *in vivo* animal model. The tumorigenesis responses of Pdc4-C1 and Pdc4-G6 transgenic mice were compared with wild-type siblings during a DMBA/TPA chemical carcinogenesis regimen. Both Pdc4-C1 ($n = 16$) and Pdc4-G6 ($n = 14$) transgenic mice displayed reduced papilloma burden compared with wild-type siblings ($n = 37$) by 45% and 65%, respectively (Fig. 4A). No tumors developed in any group with DMBA/acetone (data not shown). Benign tumor latency was delayed by 4 weeks in both transgenic Pdc4-C1 and Pdc4-G6 lines (Fig. 4B). Despite the delay in latency, the papilloma number for all mice reached a maximal level by week 24. This suggests that the papillomas are inhibited for formation rather than simply growing more slowly.

To address the possibility that the tumors that did form might have escaped Pdc4-mediated inhibition by losing Pdc4 expression, we collected a random sampling of papillomas and uninvolved epidermis from Pdc4-G6 mice. For each sample, whole-cell protein extract was harvested and the relative amounts of Pdc4 protein were determined by Western blot analysis. Interestingly, four of four Pdc4-G6 papillomas measured displayed markedly reduced Pdc4 protein levels when compared with

¹ A. Jansen et al., in preparation.




Figure 2. Pdc4 expression inhibits translation of 5' UTR structured mRNA. **A**, basal keratinocytes were cultured from wild-type and Pdc4-G6 transgenic mice. pCMV-LUC or pCMV-SL-LUC were cotransfected with pRL-TK (reporter used to control for variations in transfection efficiency). Cellular extract was collected and luciferase activity was measured. All luciferase activity was normalized to individually determined renilla luciferase activity. Translational activity of wild-type mice was arbitrarily expressed as 100%. Pdc4 overexpression decreased the translation of the stem loop luciferase transcript by 43%. *Statistical significance compared with wild-type keratinocytes ($P < 0.001$). Data are representative of three independent experiments. **B**, activated-*ras*^{Ha} was introduced via retroviral infection of both Pdc4-G6 and wild-type primary keratinocytes. Western blot analyses were done utilizing extracts with anti-Pdc4, anti-eIF4A, anti-CDK4, and anti-ODC antibodies. Samples from replicate retroviral transfections were analyzed upon the same SDS-PAGE and shown. The immunoreactive protein of ODC and CDK4 was decreased by 40% and 46%, respectively, in the K14-Pdc4 cells. Note that under conditions of activated Ras, the relative overexpression of the Pdc4 transgene seems only 2-fold higher.




Figure 3. Pcd4 expression inhibits AP-1 transactivation. Wild-type, Pcd4-C1, and Pcd4-G6 mice were bred to AP-1 luciferase reporter mice. Primary keratinocyte cultures were treated with the indicated TPA dose (or 0.1% DMSO) for 13 hours. AP-1 activity refers to luciferase activity per microgram of DNA. Pcd4 expression was inhibited (46%) both the basal and TPA-induced AP-1 activity in either Pcd4-C1 or Pcd4-G6 transgenic cells compared with wild-type cells. *Statistical significance compared with wild-type DMSO alone ($P < 0.05$). **Statistical significance compared with wild-type respective TPA treatment ($P < 0.01$). Data are representative of three independent experiments.

uninvolved epidermis (Fig. 4C). This suggests that either long-term TPA treatment down-regulates Pcd4 or that spontaneous down-regulation of elevated Pcd4 protein is selected for during papilloma development.

Following discontinuation of TPA at week 26, papillomas were followed for progression to squamous cell carcinoma (SCC). Carcinoma incidence was decreased at weeks 25 and 35 in Pcd4-C1 and Pcd4-G6 lines. Whereas 57% of wild-type siblings were positive for SCC formation, only 25% of Pcd4-C1 and 7% of higher-expressing Pcd4-G6 mice were SCC positive (Table 1). To further address the reduction of progression-to-carcinoma incidence, each papilloma was defined as an individual event and the number of carcinomas per papilloma was calculated and converted to a percentage (conversion frequency). By week 35, wild-type siblings exhibited a conversion frequency rate of 13%, whereas Pcd4-C1 and Pcd4-G6 displayed rates of 9% and 3%, respectively (Table 1). Thus, elevated Pcd4 protein levels not only decrease benign tumor development but also decrease the rate of malignant conversion.

In a number of mitotically active mouse tissues, including the glandular stomach, colon, and cervix, Pcd4-positive staining inversely correlated with positive proliferating cell nuclear antigen staining within the tissue.² This suggests that Pcd4 protein levels are higher in amitotic or more differentiated cells. To test whether Pcd4 decreased the TPA-induced mitogenic response in the epidermis, groups of three mice were treated either once or multiple times (eight times) with TPA (5 nmol/0.2 mL acetone) or acetone alone, then injected i.p. with BrdUrd 22 hours after the final TPA treatment and subsequently harvested 2 hours later. Pcd4 transgenic expression was insufficient to decrease either basal or TPA-induced mitogenic DNA replication in the epidermis.

Because increases in Pcd4 steady-state mRNA levels have been associated with cell death in certain models, we asked whether Pcd4 increased the number of apoptotic cells in the epidermis as determined by TUNEL assay. Like the BrdUrd results, with or without TPA treatment, Pcd4 transgenic expression had no effect on the percentage of TUNEL-positive cells.

Elevated Pcd4 protein expression was also not sufficient to induce basal primary keratinocytes from Pcd4-C1 or Pcd4-G6 transgenic lines to differentiate prematurely in low-calcium medium. Thus, Pcd4 transgenic expression inhibits skin tumorigenesis and tumor progression without altering TPA-induced mitogenic response, apoptosis, or terminal differentiation.

Discussion

Two lines of mice harboring a human K14 promoter-driven Pcd4 show increased Pcd4 expression targeted to the keratinocytes of the basal epidermis and the outer root sheath of the hair follicle. The K14-Pcd4 transgenic mouse shows that targeting translation initiation can be effective for cancer prevention *in vivo*. As in cell culture models, mRNA-specific inhibition of translation initiation and specific inhibition of AP-1 induction seem to contribute to the suppression of tumorigenesis by Pcd4.




Figure 4. Pcd4 delays and attenuates papilloma development in a dose-dependent manner. Pcd4-C1, Pcd4-G6, and wild-type siblings (7-8 weeks old) were initiated topically with DMBA (100 nmol). Mice were treated topically twice weekly with TPA (5 nmol per treatment) for 26 weeks. A, papilloma multiplicity (measured through 25 weeks) was reduced with Pcd4-C1 and Pcd4-G6 transgenic mice by 45% and 65%, respectively. B, papilloma incidence (percentage mice bearing papilloma) was delayed by 4 weeks in both Pcd4-C1 and Pcd4-G6 transgenic mice. All acetone mice were negative for papilloma development and not plotted. C, as mice were terminated from the experiment due to carcinoma invasion, uninvolved epidermis and papillomas were randomly chosen from wild-type and Pcd4-G6 mice. Western blot analysis of extracts was done with anti-Pcd4 antibody. An invariant nonspecific band was used for loading control comparisons.

² Unpublished data.

Table 1. Pdc4 suppresses benign tumor outgrowth and malignant conversion rate

Tumors	Wild type	C1	G6
Papillomas/mouse	5.1	2.8*	1.8*
Papilloma incidence	88%	73%	64%
Carcinoma incidence			
(25 wk)	16%	6%	0%
(35 wk)	57%	25% [†]	7% [†]
Conversion frequency			
(25 wk)	6%	2%	0%
(35 wk)	13%	9%	3% [‡]
Mice, <i>n</i>	37	16	14

NOTE: Mouse skin was initiated with a single application of DMBA (100 nmol), followed by twice weekly application of TPA (5 nmol) in 0.2 mL acetone for 26 weeks. Changes in papilloma and carcinoma development between Pdc4-G6 and Pdc4-C1 mice were compared to respective wild-type littermates.

*Two-sided $P < 0.05$ and $P < 0.005$ for comparison of papilloma burden between wild-type and C1 and wild-type and G6, respectively.

[†]Two-sided $P < 0.05$ and $P < 0.001$ for comparison of carcinoma incidence between wild-type and C1 and wild-type and G6, respectively.

[‡]Two-sided $P < 0.001$ for comparison of conversion frequency between wild type and G6.

The observation that Pdc4 inhibited both tumor promotion and tumor progression seems to be consistent with the evidence that translation initiation factors are linked to cancer pathogenesis (1, 2). Because Pdc4 interacts with and inhibits the RNA helicase eIF4A, it is plausible that Pdc4 decreases the translation efficiency of a small set of target mRNAs having highly structured 5' UTRs that require the unwinding activity of eIF4A helicase. It seems that without Pdc4, eIF4A would be left unchecked to increase the rate of inefficiently translated mRNAs, thereby causing the cells to proliferate aberrantly leading to cancer. Genes known to drive oncogenesis whose mRNAs are translationally regulated by structured 5' UTRs include insulin-like growth factor II, transforming growth factor- β , androgen receptor, CDK4, cyclin D1, p53, and ODC (reviewed in ref. 34). We show in this model that Pdc4 causes a decrease in steady-state protein levels of two of the above factors, ODC and CDK4, in primary keratinocytes infected with activated Ha Ras. The reduction in protein levels does not seem to be mediated by enhanced degradation because protein levels of ODC and CDK4 remain relatively unchanged during proteasome treatment (data not shown). However, use of proteasome inhibitor, even at low doses, causes significant death to the primary keratinocyte cultures within 8 hours. Decreases in CDK4 protein levels have been reported in Bon 1 carcinoid cells upon overexpression of Pdc4 (36). Our observations with the K14-Pdc4 mice are consistent with those for cdk4 null mice in which skin tumor development, but not induction of keratinocyte proliferation, is inhibited (37). Whereas increased proliferation can be an important contributor to tumorigenesis, it is not targeted by Pdc4 when Pdc4 inhibits tumorigenesis. This is consistent with multiple models in which inhibition of tumorigenesis can occur *without* affecting tumor promoter-induced hyperplasia caused by multiple promoters, including TPA, okadaic acid, UV, and human papillomavirus 16 E7 (21, 38–40).

Tumor promoter-induced AP-1 activity is necessary for tumor promotion in mice (21). Whereas inhibition of TPA-induced AP-1 activity provides a possible mechanism for the carcinogenesis-resistant phenotype of the K14-Pdc4 mice, it may not suffice as the two transgenic mouse lines inhibit AP-1 activity to similar levels. Reduction in tumor burden is greater in the higher-expressing Pdc4-G6 than in the lower-expressing Pdc4-C1 transgenic line. This suggests either that the carcinogenesis-resistant phenotype is independent of AP-1 inhibition or that AP-1 inhibition by Pdc4 is necessary, but not sufficient, for the reduction of tumor multiplicity to the level seen in the higher-expressing Pdc4-G6 line. Clarifying the role of AP-1 inhibition in the mechanism by which Pdc4 confers resistance to tumorigenesis and tumor progression would call for transgenic expression of Pdc4 mutants that fail to inhibit AP-1 activity and/or translation (13, 33). Whether translational inhibition via eIF4A and reduction in AP-1 activity are linked to each other in this model is not established. However, in an *in vitro* tissue culture model, Pdc4 mutants that fail to bind to eIF4A fail to inhibit both translation and TPA-induced AP-1 activity (13), providing evidence that Pdc4-specific inhibition of AP-1 activity is dependent upon and downstream of translation inhibition.

Although Pdc4 suppresses tumor induction and tumor progression as do some of the known tumor suppressors, Pdc4 differs from these tumor suppressors in apparently not being inactivated by genetic mutation in human cancer.³ Pdc4 overlaps with established tumor suppressors in the following respects: (a) Overexpression of Pdc4 in mouse skin attenuates both benign tumor development and malignant progression. (b) In a transformed cell line (mouse RT 101), expressing Pdc4 causes a reversion of tumor phenotype (16). (c) Inactivation of *PDC4* by down-regulated protein expression accompanies metastatic progression in certain of the NCI60 human tumor cell lines (27). (d) Loss of *PDC4* expression in human lung cancer correlates with tumor progression and poor patient prognosis (41). The necessity of a threshold of Pdc4 seems to be supported by the intermediate response to chemical carcinogenesis of the lower-expressing Pdc4-C1 (4-fold) transgenic line compared with the Pdc4-G6 (10-fold) line and wild-type FVB/N siblings. The relative potency of Pdc4 as a tumorigenesis inhibitor is expected to be influenced not only by protein level but also by activity status. Determining the activity of Pdc4 in papillomas or SCCs will call for the generation of stem-loop luciferase transgenic reporter mice to determine *in vivo* translation inhibitory activity. Ascertaining the levels of transgenic Pdc4 expression and activity in SCCs will provide insight into the potency and context dependency of Pdc4 suppressor activity.

Pdc4 overexpression prematurely induced withdrawal from anagen in the initial postnatal hair cycle of neonates. The regression of the hair follicle during catagen requires programmed cell death (42). Evidence suggests that premature induction of catagen is caused by early induction of apoptosis rather than decrease in proliferative capability of the hair follicle (43). The premature induction of catagen occurs in both lines of Pdc4 transgenic mice. Therefore, 4-fold overexpression of Pdc4 as determined in the Pdc4-C1 line is sufficient to cause the hair growth phenotype. Whether Pdc4 is causing premature catagen by induction of apoptosis or decrease in proliferation is under

³ A. Jansen et al., unpublished data.

investigation.⁴ Despite its name, the role of Pdc4 in programmed cell death and apoptosis remains unclear. Conflicting evidence exists as to whether the Pdc4 transcript is up- or down-regulated during induced apoptosis. Expression of the Pdc4 transcript is up-regulated in a number of apoptosis models and in senescent human diploid fibroblasts (44, 45). However, treatment of mouse lymphoma cells with topoisomerase inhibitors, which induce apoptosis, down-regulates Pdc4 transcript (46). Recently, Pdc4 expression was shown to be up-regulated by retinoic acid receptor agonists in human breast cancer cells, and Pdc4 expression was sufficient to induce apoptosis in the T47D breast cancer cell line (47). In addition, Pdc4 alters renal cancer cell response to geldanamycin from cytostatic to cytotoxic via an apoptotic mechanism mediated by G₂-M arrest (27).

Mice genetically engineered for resistance to carcinogenesis, such as Pdc4 transgenic mice, provide tools to validate molecular targets for cancer prevention (48). The generation of the K14-Pdc4 transgenic mouse and the ability of Pdc4 to target a rate-limiting process in multistage carcinogenesis provide a valuable tool for understanding the role of translational regulation in cancer development. In contrast to housekeeping

genes, many transcripts involved in growth control or oncogenesis have highly structured 5' UTRs. As Pdc4 inhibits eIF4A helicase, it is plausible to hypothesize that drugs designed to mimic Pdc4 in inhibiting eIF4A may target the altered regulation in cancer cells without changing the translation of housekeeping genes. Such a drug might have a therapeutic dose window toxic to cancer cells, yet be relatively harmless to normal tissue. Building on the premise that the protein synthesis machinery is an attractive target for therapeutic intervention, discovering specific mRNA molecules and their protein products that are regulated by Pdc4 may reveal important future targets for therapeutic consideration.

Acknowledgments

Received 7/15/2004; revised 4/4/2005; accepted 4/22/2005.

Grant support: National Cancer Institute, Department of Health and Human Services.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Elaine Fuchs (Howard Hughes Medical Institute, The Rockefeller University, New York, NY) for the K14-HGH vector; Lionel Feigenbaum and the Laboratory of Animal Sciences for oocyte injection, implantation, and founder production; Christine Perella for animal treatment and tumor scoring; Miriam Anver for pathology service; and Matthew Young, Connie Matthews, Hsin-Sheng Yang, and George Beck for insightful discussions.

⁴ A. Jansen et al., in preparation.

References

- Hershey JWB, Miyamoto S. Translational control and cancer. In: Sonenberg N, Hershey JWB, Matthews MB, editors. *Translational control of gene expression*. New York: Cold Spring Harbor Laboratory Press; 2000. p. 637-54.
- Holland EC, Sonenberg N, Pandolfi PP, Thomas G. Signaling control of mRNA translation in cancer pathogenesis. *Oncogene* 2004;23:138-44.
- Lazaris-Karatzas A, Montine KS, Sonenberg N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap. *Nature* 1990;345:544-7.
- Lazaris-Karatzas A, Smith MR, Frederickson RM, et al. Ras mediates translation initiation factor 4E-induced malignant transformation. *Genes Dev* 1992;6:1631-42.
- Ruggero D, Montanaro L, Ma L, et al. The translation factor eIF4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. *Nat Med* 2004;10:484-6.
- Herbert TP, Kilhams GR, Batty IH, Proud CG. Distinct signalling pathways mediate insulin and phorbol ester-stimulated eukaryotic initiation factor 4F assembly and protein synthesis in HEK 293 cells. *J Biol Chem* 2000; 275:11249-56.
- Eberle J, Krasagakis K, Orfanos CE. Translation initiation factor eIF4A1 mRNA is consistently overexpressed in human melanoma cells *in vitro*. *Int J Cancer* 1997;71:396-401.
- Eberle J, Fecker LF, Bittner JU, Orfanos CE, Geilen CC. Decreased proliferation of human melanoma cell lines caused by antisense RNA against translation factor eIF4A1. *Br J Cancer* 2002;86:1957-62.
- De Benedetti A, Harris AL. eIF4E expression in tumors: its possible role in progression of malignancies. *Int J Biochem Cell Biol* 1999;31:59-72.
- Bauer C, Diesinger I, Brass N, Steinhart H, Iro H, Meese EU. Translation initiation factor eIF4G is immunogenic, overexpressed, and amplified in patients with squamous cell lung carcinoma. *Cancer* 2001;92: 822-9.
- Rajasekhar VK, Viale A, Socci ND, Wiedmann M, Hu X, Holland EC. Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. *Mol Cell* 2003;12:889-901.
- Ray BK, Lawson TG, Kramer JC, et al. ATP-dependent unwinding of messenger RNA structure by eukaryotic initiation factors. *J Biol Chem* 1985;260:7651-8.
- Yang HS, Jansen AP, Komar AA, et al. The transformation suppressor Pdc4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. *Mol Cell Biol* 2003;23:26-37.
- Cmarik JL, Min H, Hegamyer G, et al. Differentially expressed protein Pdc4 inhibits tumor promoter-induced neoplastic transformation. *Proc Natl Acad Sci U S A* 1999;96:14037-42.
- Yang H-S, Jansen AP, Nair R, et al. A novel transformation suppressor, Pdc4, inhibits AP-1 transactivation but not NF- κ B or ODC transactivation. *Oncogene* 2001;20:669-76.
- Yang HS, Knies JL, Stark C, Colburn NH. Pdc4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation. *Oncogene* 2003;22:3712-20.
- Colburn NH, Former BF, Nelson KA, Yuspa SH. Tumour promoter induces anchorage independence irreversibly. *Nature* 1979;281:589-91.
- Colburn NH, Gindhart TD. Specific binding of transforming growth factor correlates with promotion of anchorage independence in EGF receptorless mouse JB6 cells. *Biochem Biophys Res Commun* 1981; 102:799-807.
- Dong Z, Ma W, Huang C, Yang CS. Inhibition of tumor promoter-induced activator protein 1 activation and cell transformation by tea polyphenols, (-)-epigallocatechin gallate, and theaflavins. *Cancer Res* 1997;57:4414-9.
- Li JJ, Rhim JS, Schlegel R, Vousden KH, Colburn NH. Expression of dominant negative Jun inhibits elevated AP-1 and NF- κ B transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes. *Oncogene* 1998; 16:2711-21.
- Young MR, Li JJ, Rincon M, et al. Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. *Proc Natl Acad Sci U S A* 1999;96:9827-32.
- Boutwell RK. The function and mechanism of promoters of carcinogenesis. *CRC Crit Rev Toxicol* 1974;2:419-43.
- Verma AK, Conrad EA, Boutwell RK. Induction of mouse epidermal ornithine decarboxylase activity and skin tumors by 7,12-dimethylben. *Carcinogenesis* 1980; 1:607-11.
- Furstenberger G, Kinzel V, Schwarz M, Marks F. Partial inversion of the initiation-promotion sequence of multistage tumorigenesis in the skin of NMRI mice. *Science* 1985;230:76-8.
- Slaga TJ, Budunova IV, Gimenez-Conti IB, Aldaz CM. The mouse skin carcinogenesis model. *J Investig Dermatol Symp Proc* 1996;1:151-6.
- Yuspa SH. Overview of carcinogenesis: past, present and future. *Carcinogenesis* 2000;21:341-4.
- Jansen AP, Camalier CE, Stark C, Colburn NH. Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity. *Mol Cancer Ther* 2004;3:103-10.
- Vassar R, Fuchs E. Transgenic mice provide new insights into the role of TGF- α during epidermal development and differentiation. *Genes Dev* 1991;5: 714-27.
- Dlugosz AA, Glick AB, Tennenbaum T, Weinberg WC, Yuspa SH. Isolation and utilization of epidermal keratinocytes for oncogene research. *Methods Enzymol* 1995;254:3-20.
- Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. *Nucleic Acids Res* 1990;18: 3587-96.
- Rincon M, Flavell RA. AP-1 transcriptional activity requires both T-cell receptor-mediated and co-stimulatory signals in primary T lymphocytes. *EMBO J* 1994; 13:4370-81.
- Svitkin YV, Pause A, Haghghat A, et al. The requirement for eukaryotic initiation factor 4A (eIF4A) in translation is in direct proportion to the degree of mRNA 5' secondary structure. *RNA* 2001;7: 382-94.
- Yang HS, Cho MH, Zakowicz H, Hegamyer G, Sonenberg N, Colburn NH. A novel function of the MA-3 domains in transformation and translation suppressor Pdc4 is essential for its binding to eukaryotic translation initiation factor 4A. *Mol Cell Biol* 2004;24:3894-906.
- Clemens MJ, Bommer UA. Translational control: the cancer connection. *Int J Biochem Cell Biol* 1999; 31:1-23.

35. Millet I, Phillips RJ, Sherwin RS, et al. Inhibition of NF- κ B activity and enhancement of apoptosis by the neuropeptide calcitonin gene-related peptide. *J Biol Chem* 2000;275:15114–21.
36. Goke R, Barth P, Schmidt A, Samans B, Lankat-Buttgereit B. Programmed cell death protein 4 suppresses CDK1/cdc2 via induction of p21(Waf1/Cip1). *Am J Physiol Cell Physiol* 2004;287:C1541–6.
37. Rodriguez-Puebla ML, Miliani de Marval PL, LaCava M, Moons DS, Kiyokawa H, Conti CJ. Cdk4 deficiency inhibits skin tumor development but does not affect normal keratinocyte proliferation. *Am J Pathol* 2002; 161:405–11.
38. Thompson EJ, MacGowan J, Young MR, Colburn N, Bowden GT. A dominant negative c-jun specifically blocks okadaic acid-induced skin tumor promotion. *Cancer Res* 2002;62:3044–7.
39. Cooper S, Young MR, Colburn N, Bowden GT. Expression of dominant negative c-jun inhibits UVB-induced squamous cell carcinoma number and size in an SKH-1 hairless mouse model. *Mole Cancer Res*. In press 2005.
40. Young MR, Farrell L, Lambert PF, Awasthi P, Colburn NH. Protection against human papillomavirus type 16-E7 oncogene-induced tumorigenesis by *in vivo* expression of dominant-negative c-jun. *Mol Carcinog* 2002;34:72–7.
41. Chen Y, Knosel T, Kristiansen G, et al. Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis. *J Pathol* 2003;200: 640–6.
42. Muller-Rover S, Handjiski B, van der Veen C, et al. A comprehensive guide for the accurate classification of murine hair follicles in distinct hair cycle stages. *J Invest Dermatol* 2001;117:3–15.
43. Pena JC, Kelekar A, Fuchs EV, Thompson CB. Manipulation of outer root sheath cell survival perturbs the hair-growth cycle. *EMBO J* 1999;18:3596–603.
44. Shibahara K, Asano M, Ishida Y, Aoki T, Koike T, Honjo T. Isolation of a novel mouse gene MA-3 that is induced upon programmed cell death. *Gene* 1995;166: 297–301.
45. Kang MJ, Ahn HS, Lee JY, Matsuhashi S, Park WY. Up-regulation of PDCD4 in senescent human diploid fibroblasts. *Biochem Biophys Res Commun* 2002;293: 617–21.
46. Onishi Y, Hashimoto S, Kizaki H. Cloning of the *TIS* gene suppressed by topoisomerase inhibitors. *Gene* 1998;215:453–9.
47. Afonja O, Juste D, Das S, Matsuhashi S, Samuels HH. Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis. *Oncogene* 2004;23: 8135–45.
48. Klatt P, Serrano M. Engineering cancer resistance in mice. *Carcinogenesis* 2003;24:817–26.

Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

Epidermal Expression of the Translation Inhibitor Programmed Cell Death 4 Suppresses Tumorigenesis

Aaron P. Jansen, Corinne E. Camalier and Nancy H. Colburn

Cancer Res 2005;65:6034-6041.

Updated version Access the most recent version of this article at:
<http://cancerres.aacrjournals.org/content/65/14/6034>

Cited articles This article cites 46 articles, 14 of which you can access for free at:
<http://cancerres.aacrjournals.org/content/65/14/6034.full#ref-list-1>

Citing articles This article has been cited by 35 HighWire-hosted articles. Access the articles at:
<http://cancerres.aacrjournals.org/content/65/14/6034.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cancerres.aacrjournals.org/content/65/14/6034>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.